Back to search results

Observational Study of Pediatric and Adult Solid Tumors for Research Repository

This is an observational study collecting biological samples (like blood, tissue, and urine) from children and adults with certain cancers, including sarcoma, endocrine tumors, neuroblastoma, retinoblastoma, and renal cancer. The goal is to create a repository, a collection of these samples, for researchers to study common childhood cancers. Researchers will analyze these samples using advanced technologies to understand cancer better. You may be able to join if you have been diagnosed with a tumor, malignancy, or pre-malignant disorder, or if you are a biological relative of someone with these conditions. The study is looking to enroll about 6035 people, and researchers will continue to analyze the collected tissues on an ongoing basis.

Study design
This is an observational study, meaning no interventions are given. It aims to enroll approximately 6035 participants.
What's involved
Biospecimens can be collected with minimal additional risk to you during sampling or procedures required for routine patient care.
Compensation
Not stated in the trial record.
Follow-up
Tissue analysis is measured on an ongoing basis.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01109394

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

Recruiting
Not specifiedAges 4+Observational
National Cancer Institute (NCI)
~6,035 participants
Updated 2026-08-04 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
tissue analysis
Measured over ongoing

Conditions

Sarcoma
Endocrine Tumors
Neuroblastoma
Retinoblastoma
Renal Cancer

Explore related trials

Central Nervous System NeoplasmEndocrine NeoplasmKidney CarcinomaLeukemiaNeuroblastomaRetinoblastomaSarcomaSolid Neoplasm

Where it's being run

5 sites across 5 states
District of Columbia1
Florida1
Maryland1
New York1
North Carolina1

Study leadership

  • Rosandra N Kaplan, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

Donna B Bernstein, R.N.
[email protected]
(240) 760-6189
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of any tumor, malignancy, pre-malignant disorder, or suspected premalignant familial syndromes, regardless, of patient age;
Biological relatives of any patient with a tumor, malignancy, pre-malignant disorder, or suspected familial pre-malignant syndrome, regardless of patient age or the diagnosis of an adult malignancy or pre-malignant disorder;
Healthy Volunteer without history of malignancy nor a family member currently being treated for cancer who are undergoing surgery, treatment or during well visits;
Biospecimens can be collected with minimal additional risk to the subject during sampling or procedures required for routine patient care.
Human samples, specimens and data collected on IRB approved protocols that are now closed
Ability of subject, Legally Authorized Representative (LAR), or parent/legal guardian of children \<=18 to understand and be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects.
Parent/caregiver of a participating pediatric or adult patient who is being treated for, or who has previously been treated for any form of pediatric cancer.
Must be able to give consent and sign the informed consent document.
Able to understand the English language.

What this trial measures

  • tissue analysisongoing

    Perform systematic molecular, genomic, proteomic, metabolomics and other high throughput ( Omics ) profiling on tumor and normal tissues